Journal: Molecular Therapy Oncology

Article Title: Stem cell-directed targeted chemotherapy primes drug-resistant metastatic ovarian tumors for elimination by natural killer cells

doi: 10.1016/j.omton.2026.201214

Figure Lengend Snippet: Evaluation of MICA/B expression on the surface of CSCs and its correlation with sensitivity to laNK92 cells (A–F) Flow cytometry analysis of OV-031-T, OV-172-M, and OV-054-R ovarian CSCs extracted from tumorspheres before (Ctrl) and after treatment with SN38 or 5-FU. n = 3 flasks, biological replicates. (G–I) Measurement of NK cell-mediated toxicity to PDCs using a cell viability assay. This figure shows that treatment of CSCs with SN38 or 5-FU upregulates expression of MICA/B on CSCs making them more vulnerable to NK cells. The data are presented as mean ± SD, n = 3 wells, biological replicates, ∗∗ p < 0.01.

Article Snippet: Three days post-transduction, the transduced OV-031-T, OV-172-M, or OV-054-R cell populations were treated with puromycin (InvivoGen, Cat# ant-pr-1) at final concentrations of 2, 0.5, and 1 μg/mL, respectively, for 1 week to select for fLuc-expressing cells.

Techniques: Expressing, Flow Cytometry, Viability Assay

Journal: Molecular Therapy Oncology

Article Title: Stem cell-directed targeted chemotherapy primes drug-resistant metastatic ovarian tumors for elimination by natural killer cells

doi: 10.1016/j.omton.2026.201214

Figure Lengend Snippet: Evaluation of the ability of laNK92 cells to eliminate SN38/5-FU-treated metastatic ovarian cancer cells in vivo (A, D, G) Bioluminescent imaging of CIEA NOG mice that were implanted with untreated and drug-treated OV-031-T n = 3, OV-172-M n = 4, and OV-054-R n = 4 cancer cells, followed by i.p. injection of laNK92 cells. (B, E, H) qBLI of the change in tumor burden (untreated and drug-treated) after injection of laNK92 cells over the 30-day period. (C, F, I) Statistical analysis of fold change in BLI between untreated and drug-treated cancer cells after NK therapy. This fold change in BLI corresponds to the change in tumor burden over the 30-day period. Data are presented as mean ± SD, t test, ∗ p < 0.05.

Article Snippet: Three days post-transduction, the transduced OV-031-T, OV-172-M, or OV-054-R cell populations were treated with puromycin (InvivoGen, Cat# ant-pr-1) at final concentrations of 2, 0.5, and 1 μg/mL, respectively, for 1 week to select for fLuc-expressing cells.

Techniques: In Vivo, Imaging, Injection

Journal: Molecular Therapy Oncology

Article Title: Stem cell-directed targeted chemotherapy primes drug-resistant metastatic ovarian tumors for elimination by natural killer cells

doi: 10.1016/j.omton.2026.201214

Figure Lengend Snippet: Bioluminescent imaging of OV-031-T, OV-172-M, and OV-054-R ovarian tumors, shown in green, and ASC-shCE2:yCD cells, shown in red, in mice over a three-day period Post euthanasia, OV-031-T (A), OV-172-M (B), and OV-054-R (C) tumors and organs were removed and imaged after addition of furimazine, which is a substrate for nLuc. This figure shows active localization of ASC-shCE2:yCD cells in ovarian tumors, validating their tumor tropic properties; n = 1 mouse per cell line.

Article Snippet: Three days post-transduction, the transduced OV-031-T, OV-172-M, or OV-054-R cell populations were treated with puromycin (InvivoGen, Cat# ant-pr-1) at final concentrations of 2, 0.5, and 1 μg/mL, respectively, for 1 week to select for fLuc-expressing cells.

Techniques: Imaging

Journal: Molecular Therapy Oncology

Article Title: Stem cell-directed targeted chemotherapy primes drug-resistant metastatic ovarian tumors for elimination by natural killer cells

doi: 10.1016/j.omton.2026.201214

Figure Lengend Snippet: Evaluation of therapy responses and cancer relapses by BLI in CIEA NOG mice bearing OV-054-R tumors (A) qBLI of mice in the untreated group, n = 5 mice. (B) qBLI of mice treated with irinotecan, 25 mg/kg, and 5-FC, 350 mg/kg, twice per week, n = 5 mice. (C) qBLI of mice treated with ASC-shCE2:yCD cells once per week plus irinotecan, 35 mg/kg, and 5-FC, 350 mg/kg, twice per week for 11 weeks, followed by 5 weeks of therapy with laNK92-nLuc cells, n = 4, 1 additional mouse for IHC. The blue arrows point to the days laNK92-nLuc cells were injected. The number of animals per group was estimated based on pilot studies, providing sufficient power to avoid type I and type II errors. The dashed line at 1 ×10 6 , radiance, shows the background bioluminescence of mice without any tumors. (D) IHC of excised OV-054-R tumor tissue from the ASC-treated group versus the untreated control group using an anti-GFP primary antibody. (E) BLI, nLuc imaging, of laNK92-nLuc cells, validating the viability of the NK cells during the immunotherapy phase. (F) Measurement of mouse body weight during the immunotherapy phase.

Article Snippet: Three days post-transduction, the transduced OV-031-T, OV-172-M, or OV-054-R cell populations were treated with puromycin (InvivoGen, Cat# ant-pr-1) at final concentrations of 2, 0.5, and 1 μg/mL, respectively, for 1 week to select for fLuc-expressing cells.

Techniques: Injection, Control, Imaging